Farnesyl:protein transferase inhibitors as potential agents for the management of human prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 4, Issue 1, 2001, Pages 33-43

  Sepp Lorenzino, L ^a   Tjaden, G ^a   Moasser, M M ^a   Timaul, N ^a   Ma, Z ^a   Kohl, N E ^b   Gibbs, J B ^b   Oliff, A ^b   Rosen, N ^a   Scher, H I ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Prenylation; Ras

Indexed keywords

2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER; ANTIANDROGEN; BICALUTAMIDE; CISPLATIN; DOXORUBICIN; ESTRAMUSTINE; ETOPOSIDE; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN;

ANCHORAGE INDEPENDENT GROWTH; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INHIBITION; CELL CYCLE; CELL TRANSFORMATION; CELLULAR DISTRIBUTION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOSOL; DRUG EFFECT; DRUG SCREENING; DRUG SENSITIVITY; GAMMA RADIATION; GENE ACTIVATION; GENE MUTATION; HORMONE DEPENDENCE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; MUTANT; ONCOGENE; ONCOGENE H RAS; ONCOGENE N RAS; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN LOCALIZATION; PROTEIN PROCESSING; TUMOR SUPPRESSOR GENE;

EID: 0035055557     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500491     Document Type: Article

References (48)

1. Clinical trials in relapsed prostate cancer
2. Targeted therapy for prostate cancer: The Memorial Sloan-Kettering Cancer Center approach
3. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics
4. Farnesyltransferase inhibitors and cancer treatment: Targeting simply Ras?
5. A peptidomimetic inhibitor of farnesyl:-P]rotein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines
6. A farnesyl:Protein transferase inhibitor induces p21 expression and G1 block in p53-wild type tumor cells
7. Ras gene mutations in human prostate cancer
8. A peptidomimetic inhibitor of Ras functionality markedly suppresses growth of human prostate tumor xenografts in mice: Prospects for long-term clinical utility
9. 2-Substituted piperazines as constrained amino acids. Application to the synthesis of potent, non carboxylic acid inhibitors of farnesyltransferase
10. Cell cycle-dependent, differential prenylation of proteins
11. Light scatter of isolated cell nuclei as a parameter discriminating the cell-cycle subcompartments
12. Flow cytometric detection of mitotic cells using bromodeoxyuridine/DNA technique in combination with 90 degrees and forward scatter measurements
13. The farnesyl protein transferase inhibitor BZA-5B blocks farnesylation of nuclear lamins and p21ras but does not affect their function or localization
14. LNCaP model of human prostatic carcinoma
15. Studies on the human prostatic cancer cell line LNCaP
16. The median effect principle and the combination index for quantitation of synergism and antagonism
17. V-rasH expression confers hormone-independent in vitro growth to LNCaP prostate carcinoma cells
18. Progression of prostatic intraepithelial neoplasia to invasive carcinoma in C3(1)/SV4O large T antigen transgenic mice: Histopathological and molecular biological alterations
19. Expression of transforming growth factor-alpha and the epidermal growth factor receptor in human prostate tissues
20. Suppression of various human tumor cell lines by a dominant negative H-ras mutant
21. Partial growth suppression of human prostate cancer cells by the Krev-1 suppressor gene
22. Presence of ras oncogene mutations and human papillomavirus DNA in human prostate carcinomas
23. Infrequent RAS oncogene mutations in human prostate cancer
24. State of adenomatous polyposis coli gene and ras oncogenes in Japanese prostate cancer
25. Comparison of ras activation in prostate carcinoma in Japanese and American men
26. Mutational status of codons 12 and 13 of the N- and K-ras genes in tissue and cell lines derived from primary and metastatic prostate carcinomas
27. Activated ras alleles in human carcinoma of the prostate are rare
28. Immunohistochemical staining of ras p21: Staining in benign and malignant prostate tissue
29. Protein prenylation: Molecular mechanisms and functional consequences
30. Heterotransplantation of a human prostatic adenocarcinoma cell line in nude mice
31. p53 Oncogene mutations in three human prostate cancer cell lines
32. Establishment and characterization of a human prostatic carcinoma cell line (PC3)
33. Establishment of a new prostatic carcinoma cell line (TSU-Pr1)
34. Protein geranylgeranylation, not farnesylation, is required for the G1 to S phase transition in mouse fibroblasts
35. The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21 (WAF1/CIP1/SDI1) in a p53-independent manner
36. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts
37. Resistance of K-RasBV12 proteins to farnesyltransferase inhibitors in Rat1 cells
38. Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo
39. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors
40. Characterization of Ha-ras, N-ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I
41. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice
42. Peptidomimetic inhibitors of ras farnesylation and function in whole cells
43. Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton
44. Resistance of a variant ras-transformed cell line to phenotypic reversion by farnesyl transferase inhibitors
45. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice
46. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis
47. Farnesyl-transferase inhibitors alter the prenylation and growth-stimulating function of rhoB
48. Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment